0M3Q Stock Overview
Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$159.32 |
| 52 Week High | US$200.29 |
| 52 Week Low | US$144.82 |
| Beta | 0.89 |
| 1 Month Change | -4.38% |
| 3 Month Change | -10.07% |
| 1 Year Change | -19.05% |
| 3 Year Change | -18.29% |
| 5 Year Change | 21.84% |
| Change since IPO | 98.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0M3Q | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.2% | 0.2% | -0.9% |
| 1Y | -19.0% | 7.4% | 9.8% |
Return vs Industry: 0M3Q underperformed the UK Pharmaceuticals industry which returned 7.4% over the past year.
Return vs Market: 0M3Q underperformed the UK Market which returned 9.8% over the past year.
Price Volatility
| 0M3Q volatility | |
|---|---|
| 0M3Q Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0M3Q has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0M3Q's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1950 | 13,800 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
Zoetis Inc. Fundamentals Summary
| 0M3Q fundamental statistics | |
|---|---|
| Market cap | US$71.85b |
| Earnings (TTM) | US$2.49b |
| Revenue (TTM) | US$9.26b |
28.9x
P/E Ratio7.8x
P/S RatioIs 0M3Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0M3Q income statement (TTM) | |
|---|---|
| Revenue | US$9.26b |
| Cost of Revenue | US$2.72b |
| Gross Profit | US$6.54b |
| Other Expenses | US$4.05b |
| Earnings | US$2.49b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.55 |
| Gross Margin | 70.64% |
| Net Profit Margin | 26.86% |
| Debt/Equity Ratio | 138.3% |
How did 0M3Q perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield32%
Payout RatioDoes 0M3Q pay a reliable dividends?
See 0M3Q dividend history and benchmarks| Zoetis dividend dates | |
|---|---|
| Ex Dividend Date | Jan 21 2025 |
| Dividend Pay Date | Mar 04 2025 |
| Days until Ex dividend | 32 days |
| Days until Dividend pay date | 10 days |
Does 0M3Q pay a reliable dividends?
See 0M3Q dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 05:54 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zoetis Inc. is covered by 42 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Balaji Prasad | Barclays |